BMRN

BioMarin Pharmaceutical Inc (BMRN) | Rumor.io

BioMarin Pharmaceutical

BMRN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,411

Bullish sentiment (50-day avg)98%

Price to earnings ratio160.9

Market capitalization11.5B

Earnings per share0.37

Dividend yield (TTM)—

Revenue (annual)3.2B

Net income (annual)348.9M

Social

What share of all stock conversation is about BMRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% +0

Aug 31

BioMarin Pharmaceutical Inc. (BMRN) has reached a global settlement with Ascendis Pharma A/S, resolving patent disputes and establishing royalties on Yuviwel sales in the US, EU, Brazil, and South Korea.
Ascendis will pay BioMarin a 20% royalty on Yuviwel sales in the US and an 18% royalty in the EU, Brazil, and South Korea, effective until 2030.
BioMarin's stock price has increased due to the settlement, with a 3.3% premarket advance and a 1.3% gain overall.

Generated by AI

Sentiment

Of the messages about BMRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	75% -25	83.16% -11.55
Bearish	—	—	25% new	16.84% +11.55

Bullish· Dec 19

BioMarin Pharmaceutical Inc. (BMRN) is expanding its position as a leader in rare diseases through its acquisition of Amicus Therapeutics for $4.8 billion.
The acquisition is expected to accelerate revenue growth and strengthen BioMarin's financial outlook, with Amicus's products generating $599 million in revenue.
The deal is seen as a transformative acquisition that could propel BioMarin's stock to $100 or more by 2026, with many investors believing the company is still undervalued despite the recent 20% price increase.

Bearish· Aug 20

* BioMarin Pharmaceutical's ($BMRN) valuation has been inflated by buyout premiums, which were eliminated by the recent drop, revealing high expectations.
* A $32 price target for Sangamo Therapeutics ($SGMO) assumes a large portion of hemophilia patients will opt for BioMarin's gene therapy, but this may not be the case by 2022.
* BioMarin's gene therapy franchise could be severely impacted if patients in clinical trials are forced to return to using extraneous Factor VIII by 2022.

Generated by AI

Topics

Of the messages about BMRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	95.12%	11.54%
Analysts	0%	0%	3.66%	42.27%
Macro	0%	0%	1.22%	42.64%
Earnings	0%	0%	0%	0.49%
Controversies	0%	0%	0%	0.24%
Technical Analysis	0%	0%	0%	2.82%

Earnings· Apr 26

BioMarin Pharmaceutical's (BMRN) Q1 earnings report showed a non-GAAP EPS of $0.60, beating estimates by $0.42, and revenue of $596.4M, beating estimates by $25.1M.
The company reaffirmed its FY23 EPS guidance of $1.80-2.05 and updated its revenue guidance to $2.375-2.500 billion.
BioMarin's Q1 revenue grew 15% year-over-year, driven by a 3.4% increase in Vimizim revenue and a 5% increase in total revenue.

Analysts· Nov 22

BioMarin Pharmaceutical's price target was raised by multiple analysts, including JPMorgan Chase to $135.00, SVB Leerink to $115.00, Credit Suisse to $105.00, and Morgan Stanley to $90.00.
Analysts at William Blair, SVB Leerink, Credit Suisse, and Morgan Stanley upgraded their ratings on BioMarin Pharmaceutical to Outperform or raised their price targets, citing FDA approval of Voxzogo.
Analysts at William Blair, SVB Leerink, Credit Suisse, and Morgan Stanley have provided positive outlooks on BioMarin Pharmaceutical, with price targets ranging from $90.00 to $135.00.

Announcements· Dec 19

BioMarin Pharmaceutical Inc. ($BMRN) to acquire Amicus Therapeutics ($FOLD) for $4.8 billion in an all-cash transaction, expanding its position as a leader in rare diseases and accelerating revenue growth.
The acquisition adds two marketed, high-growth products, Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe disease, with $599 million in revenue over the past four quarters.
The deal is expected to close in Q2 2026, subject to approvals and shareholder vote, and is expected to enhance BioMarin's rare disease leadership and provide strong future growth and EPS accretion.

Generated by AI

Community

Of the messages about BMRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	60%	63.96%	67.82%
Newcomers	100%	40%	36.04%	32.18%

Regulars· Dec 19

BioMarin Pharmaceutical Inc. (BMRN) is acquiring Amicus Therapeutics (FOLD) for $4.8 billion in an all-cash deal, with a purchase price of $14.50 per share.
The acquisition is expected to close in Q2 2026, subject to regulatory approvals and shareholder approval, and will add three new rare disease products to BioMarin's portfolio, including Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease.
The deal represents a 33% premium to Amicus Therapeutics' December 18 close, and a 46% premium to its 30-day volume-weighted average price (VWAP) and a 58% premium to its 60-day VWAP.

Newcomers· Dec 19

BioMarin Pharmaceutical Inc. (BMRN) is acquiring Amicus Therapeutics (FOLD) for $4.8 billion, expanding its position in rare diseases and accelerating revenue growth.
The acquisition will add two high-growth products with $599 million in revenue over the past four quarters, including Galafold for Fabry disease and Opfolda for Pompe disease.
The deal is expected to close in the second quarter of 2026, pending regulatory approval, and has triggered strong conviction buying, a clear takeover premium, and market approval of strategic rare-disease consolidation.

Generated by AI

News

BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. stock outlook: Q4 2026–2027 catalysts, DMD BMN 351 data, Voxzogo approval potential, and raised guidance. Click for this BMRN update.

8d agoSeeking Alpha

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?

BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy for BioMarin Pharmaceutical, with the share price down 7.77% over 30 days, even after a 16.91% 90 day share price return and a 17.62% total shareholder return over the past year. This points to momentum cooling in the short term despite...

10d agofinance.yahoo.com

Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?

BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug’s use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The combination of strong late-stage VOXZOGO data in an indication with no approved treatments and the addition of a seasoned R&D executive to the board underscores...

11d agofinance.yahoo.com

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone

BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley

11d agoYahoo Finance

BioMarin options flow shows large bullish call spread targeting $100 by April 2027

12d agoInvesting.com

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

13d agoYahoo Finance

Also Discussed

Investors talking about BMRN also mention

#	Name	Attention
1	PTC Therapeutics, Inc.PTCT	0%new
2	Alnylam Pharmaceuticals, Inc.ALNY	0%0
3	Sarepta Therapeutics, Inc.SRPT	0%-0.01
4	BLUE - bluebird bio, Inc.	——
5	Agios Pharmaceuticals, Inc.AGIO	0%0
6	SGMO - Sangamo Therapeutics, Inc.	——
7	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
8	uniQure N.V.QURE	0.02%+0.01
9	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
10	Ionis Pharmaceuticals, Inc.IONS	0%new

BioMarin Pharmaceutical Inc

Healthcare
Biotechnology

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.

Website

Location

770 Lindaro Street

San Rafael, CA, 94901

United States

Social

What share of all stock conversation is about BMRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% +0

Aug 31

BioMarin Pharmaceutical Inc. (BMRN) has reached a global settlement with Ascendis Pharma A/S, resolving patent disputes and establishing royalties on Yuviwel sales in the US, EU, Brazil, and South Korea.
Ascendis will pay BioMarin a 20% royalty on Yuviwel sales in the US and an 18% royalty in the EU, Brazil, and South Korea, effective until 2030.
BioMarin's stock price has increased due to the settlement, with a 3.3% premarket advance and a 1.3% gain overall.

Generated by AI

Sentiment

Of the messages about BMRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	75% -25	83.16% -11.55
Bearish	—	—	25% new	16.84% +11.55

Bullish· Dec 19

BioMarin Pharmaceutical Inc. (BMRN) is expanding its position as a leader in rare diseases through its acquisition of Amicus Therapeutics for $4.8 billion.
The acquisition is expected to accelerate revenue growth and strengthen BioMarin's financial outlook, with Amicus's products generating $599 million in revenue.
The deal is seen as a transformative acquisition that could propel BioMarin's stock to $100 or more by 2026, with many investors believing the company is still undervalued despite the recent 20% price increase.

Bearish· Aug 20

* BioMarin Pharmaceutical's ($BMRN) valuation has been inflated by buyout premiums, which were eliminated by the recent drop, revealing high expectations.
* A $32 price target for Sangamo Therapeutics ($SGMO) assumes a large portion of hemophilia patients will opt for BioMarin's gene therapy, but this may not be the case by 2022.
* BioMarin's gene therapy franchise could be severely impacted if patients in clinical trials are forced to return to using extraneous Factor VIII by 2022.

Generated by AI

Topics

Of the messages about BMRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	95.12%	11.54%
Analysts	0%	0%	3.66%	42.27%
Macro	0%	0%	1.22%	42.64%
Earnings	0%	0%	0%	0.49%
Controversies	0%	0%	0%	0.24%
Technical Analysis	0%	0%	0%	2.82%

Earnings· Apr 26

BioMarin Pharmaceutical's (BMRN) Q1 earnings report showed a non-GAAP EPS of $0.60, beating estimates by $0.42, and revenue of $596.4M, beating estimates by $25.1M.
The company reaffirmed its FY23 EPS guidance of $1.80-2.05 and updated its revenue guidance to $2.375-2.500 billion.
BioMarin's Q1 revenue grew 15% year-over-year, driven by a 3.4% increase in Vimizim revenue and a 5% increase in total revenue.

Analysts· Nov 22

BioMarin Pharmaceutical's price target was raised by multiple analysts, including JPMorgan Chase to $135.00, SVB Leerink to $115.00, Credit Suisse to $105.00, and Morgan Stanley to $90.00.
Analysts at William Blair, SVB Leerink, Credit Suisse, and Morgan Stanley upgraded their ratings on BioMarin Pharmaceutical to Outperform or raised their price targets, citing FDA approval of Voxzogo.
Analysts at William Blair, SVB Leerink, Credit Suisse, and Morgan Stanley have provided positive outlooks on BioMarin Pharmaceutical, with price targets ranging from $90.00 to $135.00.

Announcements· Dec 19

BioMarin Pharmaceutical Inc. ($BMRN) to acquire Amicus Therapeutics ($FOLD) for $4.8 billion in an all-cash transaction, expanding its position as a leader in rare diseases and accelerating revenue growth.
The acquisition adds two marketed, high-growth products, Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe disease, with $599 million in revenue over the past four quarters.
The deal is expected to close in Q2 2026, subject to approvals and shareholder vote, and is expected to enhance BioMarin's rare disease leadership and provide strong future growth and EPS accretion.

Generated by AI

Community

Of the messages about BMRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	60%	63.96%	67.82%
Newcomers	100%	40%	36.04%	32.18%

Regulars· Dec 19

BioMarin Pharmaceutical Inc. (BMRN) is acquiring Amicus Therapeutics (FOLD) for $4.8 billion in an all-cash deal, with a purchase price of $14.50 per share.
The acquisition is expected to close in Q2 2026, subject to regulatory approvals and shareholder approval, and will add three new rare disease products to BioMarin's portfolio, including Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease.
The deal represents a 33% premium to Amicus Therapeutics' December 18 close, and a 46% premium to its 30-day volume-weighted average price (VWAP) and a 58% premium to its 60-day VWAP.

Newcomers· Dec 19

BioMarin Pharmaceutical Inc. (BMRN) is acquiring Amicus Therapeutics (FOLD) for $4.8 billion, expanding its position in rare diseases and accelerating revenue growth.
The acquisition will add two high-growth products with $599 million in revenue over the past four quarters, including Galafold for Fabry disease and Opfolda for Pompe disease.
The deal is expected to close in the second quarter of 2026, pending regulatory approval, and has triggered strong conviction buying, a clear takeover premium, and market approval of strategic rare-disease consolidation.

Generated by AI

BioMarin Pharmaceutical

Social

Aug 31

Bullish· Dec 19

Bearish· Aug 20

Earnings· Apr 26

Analysts· Nov 22

Announcements· Dec 19

Regulars· Dec 19

Newcomers· Dec 19

BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN)

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?

Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone

BioMarin options flow shows large bullish call spread targeting $100 by April 2027

BioMarin Stops Voxzogo Development for Noonan Syndrome

Also Discussed

BioMarin Pharmaceutical Inc

Company Information

Location

BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN)

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?

Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone

BioMarin options flow shows large bullish call spread targeting $100 by April 2027

BioMarin Stops Voxzogo Development for Noonan Syndrome

Also Discussed

Social

Aug 31

Bullish· Dec 19

Bearish· Aug 20

Earnings· Apr 26

Analysts· Nov 22

Announcements· Dec 19

Regulars· Dec 19

Newcomers· Dec 19